The company has a diverse and highly experienced Board, committed to seeing the Sienna diagnostic tests adopted by the medical profession and researchers, providing a genuine benefit to the public. The Board consists of five members, each with significant commercial and management experience:

Geoff Cumming Chairman

Geoff Cumming, BSc (Hons), BAppSc, MAICD, MBA, PhD, Chairman of Sienna, was appointed to the Sienna Board in 2006. Geoff has held senior roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania) Geoff transformed the loss-making entity the Swiss parent was intending to divest, into the fastest growing and most profitable affiliate in the Roche group. In his role as Managing Director/CEO of Biosceptre International Ltd, Geoff was successful in designing and securing key funding arrangements through a skilful range of capital raising initiatives, including large government grants, partnering and co-development deals.  

His most recent executive role was as Managing Director / CEO of Anteo Diagnostics Ltd (ASX: ADO). He is currently a Non-executive Director of Anteo Diagnostics Ltd and Medical Australia Ltd (ASX: MLA).

Helen Fisher Non-Executive Director

Helen Fisher, BSc, LLB (Hons), LLM, MCom, is a passionate leader with a rare combination of financial expertise and deep knowledge and global networks in the Life Sciences industry. Helen is CEO and Managing Director of Bio Capital Impact Fund. Prior to establishing the Fund, Helen was a partner of Deloitte and led Deloitte’s Life Sciences industry practice in Australia for 5 years, having had many years’ experience in the Life Sciences and Health Care industry. She also specialised in Financial Services Industry, servicing some of the largest banks and funds in the Funds Management industry and has been involved in setting up a number of large international funds, as well as advised on a number of significant M&A deals.

Helen provided strategic tax advice to publicly listed and large multinational companies and has extensive experience with capital raisings, licensing deals, demergers, implementing offshore structures, IP management and location, and supply chain management. Helen has Bachelor degrees in Law (with Honours) and Science from the University of Melbourne, a Masters degree in Laws (specialising in International Taxation) from the University of Melbourne and a Masters degree in Commerce from the University of NSW. Helen is a Chartered Tax Adviser and an affiliate member of Chartered Accountants Australia and New Zealand. Helen is the Chair of the Victorian branch of AusBiotech.

John Chiplin Non-Executive Director

John Chiplin B.Pharm PhD is a very experienced healthcare executive and brings considerable capital markets experience to the Sienna Board. His most recent executive position was CEO of Polynoma LLC, a US based cancer immunotherapy company, and he was formerly the founding CEO of ASX listed Arana Therapeutics Ltd prior to that company’s acquisition by Cephalon (now Teva). Before his appointment at Arana Dr Chiplin was head of the UK’s $300M ITI Life Science investment fund.

He is currently a Non-Executive Director of ASX listed biotechnology companies Benitec Biopharma (ASX:BLT) and Cynata Therapeutics (ASX:CYP), as well as Adalta Ltd (ASX:1AD), and Chairman of UK AIM listed company Scancell Holdings Plc (AIM:SCLP). Dr Chiplin is also the founder and Managing Director of Newstar Ventures, an early stage investment fund.

Carl Stubbings Non-Executive Director 

Carl Stubbings, BSc, joined Sienna’s Board in December 2011. Carl has considerable experience commercialising diagnostic products, both locally and globally. Based in the USA for 13 years, he served as Vice-President of Sales and Marketing for Focus Diagnostics, a subsidiary of Quest Diagnostics, one of the world’s largest pathology laboratories. In July 2012, Carl moved back to Australia and has held roles at Benitec Biopharma Limited (an ASX-listed biotechnology company), where he was Chief Business Officer, and more recently as Head of Commercialisation at BCAL Diagnostics, a start-up company developing a blood test for breast cancer. 

In addition to his executive roles, Carl is also a Non-executive Director of ASX listed medical device company Analytica Medical Limited and Otakaro Pathways, a New Zealand based company developing a diagnostic test for Crohn’s disease.

David J. Earp Non-Executive Director

David J. Earp, BSc (Hons), J.D., Ph.D. joined the Sienna Board in December 2012.  David was a partner in an intellectual property law firm, advising life science clients, prior to taking senior roles in a number of biotechnology companies.  From 1999 until 2012, David served in various roles at Geron Corporation (Menlo Park, California), a NASDAQ listed company, including chief patent counsel, chief legal officer and senior vice president of corporate transactions.  From 2005 to 2010, David was a board member of TA Therapeutics Ltd. (Hong Kong, PRC). He served on the board of ViaGen Corporation (Austin, Texas) from 2008 – 2012, including as executive chairman from 2010 – 2012 when the company was acquired in a trade sale.  He is presently the president, CEO and a director of Circle Pharma, an early stage biotechnology company located in San Francisco, California.

David holds a BSC with First Class Honours from Leeds University (UK), a PhD in biochemistry from Cambridge University (UK) and a JD from Lewis and Clark Northwestern School of Law (Portland, Oregon).

Sign up for updates